Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT05046483 Sponsor: German Diabetes Center Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT05046483
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have recently had a type of heart attack called a STEMI (where a specific pattern shows up on a heart tracing)
  • People aged 18 to 80 years
  • People whose blood sugar control measure (HbA1c) is below 9.0%
  • People who have been diagnosed with diabetes, based on an HbA1c of 6.5% or above and/or an abnormal blood sugar response test
  • People with normal blood sugar levels, based on an HbA1c below 5.7% and a normal blood sugar response test
  • People with "prediabetes" (blood sugar levels that are higher than normal but not yet in the diabetes range), based on specific blood sugar or HbA1c readings between 5.7% and 6.4%
  • People who are able to give informed consent, are medically stable, and are not currently on sedating medications (such as strong painkillers) or certain other medications that could interfere with the study

Who may not be able to join:

  • People with certain specific types of diabetes as classified by medical guidelines, or gestational diabetes (diabetes during pregnancy)
  • People who are currently pregnant
  • People who have an active infection or fever
  • People who are taking medications that suppress the immune system
  • People with severe long-term kidney, liver, or heart disease (confirm with trial site for specific measurements)
  • People with a current or active cancer diagnosis
  • People with a severe long-term psychiatric illness or substance addiction
  • People who are currently taking part in another clinical intervention trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Roden, Prof., MD, German Diabetes Center

Phone: +49-211-3382-0

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
German Diabetes Center
Registry
ClinicalTrials.gov
Start date
30 December 2018
Est. completion
30 December 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Change of cardiac function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov